AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31450983 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin-sitagliptin (LS); luseogliflozin 2.5 mg for 0-12 weeks, then luseogliflozin plus sitagliptin 50 mg for 12-24 weeks
Number of subjects: 41
Study 31450983 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin-luseogliflozin (SL); sitagliptin 50 mg for 0-12 weeks, then sitagliptin plus luseogliflozin 2.5 mg for 12-24 weeks
Number of subjects: 41
Study 28629472 — intervention group
Group type: EXPERIMENTAL
Intervention: S100 measured at 24 hours after OHCA
Number of subjects: 687
Study 28629472 — intervention group
Group type: EXPERIMENTAL
Intervention: S100 measured at 48 hours after OHCA
Number of subjects: 687
Study 28629472 — intervention group
Group type: EXPERIMENTAL
Intervention: S100 measured at 72 hours after OHCA
Number of subjects: 687
Study 28629472 — intervention group
Group type: EXPERIMENTAL
Intervention: S100 levels at 24 hours in 33 °C group
Number of subjects: 687
Study 28629472 — intervention group
Group type: EXPERIMENTAL
Intervention: S100 levels at 72 hours in 33 °C group
Number of subjects: 687
Study 28629472 — intervention group
Group type: EXPERIMENTAL
Intervention: S100 added to prognostication model including baseline variables and target temperature
Number of subjects: 687
Study 28629472 — intervention group
Group type: EXPERIMENTAL
Intervention: S100 in multivariable analyses
Number of subjects: 687
Study 28629472 — intervention group
Group type: EXPERIMENTAL
Intervention: S100 added to model including neuron-specific enolase (NSE)
Number of subjects: 687
Study 27391598 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate (1.4 mg/m² on days 1 and 8 every 21 days)
Number of subjects: 1864
Study 27391598 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (1.25 g/m² twice daily on days 1-14 every 21 days)
Number of subjects: 1864
Study 27391598 — intervention group
Group type: COMPARATOR
Intervention: Treatment of physician's choice
Number of subjects: 1864
Study 27391598 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin (as above)
Number of subjects: 1864
Study 27391598 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (as above)
Number of subjects: 1864
Study 23098678 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (200 mg and 400 mg)
Number of subjects: 9
Study 23098678 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (20 mg and 40 mg)
Number of subjects: 9
Study 23098678 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine (100 mg and 200 mg)
Number of subjects: 9
Study 23098678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 21725510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent sustained-release sodium-fluoride (50 mg) with colecalciferol (1000 IU) and calcium-citrate (800 mg)
Number of subjects: 66
Study 21725510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate (1 mg/3-monthly)
Number of subjects: 66
Study 21725510 — intervention group
Group type: COMPARATOR
Intervention: Sodium-fluoride
Number of subjects: 66
Study 19515090 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted dosing
Number of subjects: 13219
Study 19515090 — intervention group
Group type: COMPARATOR
Intervention: Manual dosing
Number of subjects: 13219
Study 16995870 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 12
Study 16995870 — intervention group
Group type: COMPARATOR
Intervention: Sun Drop
Number of subjects: 12
Study 16995870 — intervention group
Group type: COMPARATOR
Intervention: Fresca
Number of subjects: 12
Study 16995870 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study 15186867 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based counselling programme
Number of subjects: 63
Study 11422129 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite (HDM) extract
Number of subjects: 20
Study 11422129 — intervention group
Group type: COMPARATOR
Intervention: Isolated major allergens (Der p 1 and Der p 2)
Number of subjects: 20
Study 10193286 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 3 mg kg-1
Number of subjects: 40
Study 10193286 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.2 mg kg-1
Number of subjects: 40
Study 8092425 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual therapy with a solution of purified, standardized allergen preparation (Stallergènes)
Number of subjects: 58
Study 8092425 — intervention group
Group type: COMPARATOR
Intervention: matched placebo
Number of subjects: 58
Study 3276185 — intervention group
Group type: EXPERIMENTAL
Intervention: Max-EPA (omega-3 PUFAs, 3.2 g eicosapentaenoic acid and 2.2 g docosahexaenoic acid daily)
Number of subjects: 8
Study 3276185 — intervention group
Group type: EXPERIMENTAL
Intervention: Max-EPA (omega-3 PUFAs)
Number of subjects: 8
Study 31372823 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment for 4 weeks
Number of subjects: 90
Study 31372823 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment for 4 weeks (per-protocol analysis)
Number of subjects: 90
Study 31372823 — intervention group
Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 90
Study 30189281 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral lateral rectus recession (BLRc)
Number of subjects: 197
Study 30189281 — intervention group
Group type: COMPARATOR
Intervention: Unilateral lateral rectus recession combined with medial rectus resection (R&R)
Number of subjects: 197
Study 28477228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (300 µg) with intravenous patient-controlled analgesia (IV-PCA)
Number of subjects: 30
Study 28477228 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (IV-PCA) only
Number of subjects: 30
Study 28477228 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 26439700 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus cisplatin (CS group)
Number of subjects: 236
Study 26439700 — intervention group
Group type: COMPARATOR
Intervention: 5-FU plus cisplatin (CF group)
Number of subjects: 236
Study 23062958 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniscrews with septum width ≤3 mm
Number of subjects: 40
Study 23062958 — intervention group
Group type: COMPARATOR
Intervention: Miniscrews with septum width >3 mm
Number of subjects: 40
Study 21718543 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based screen time intervention
Number of subjects: 270
Study 21718543 — intervention group
Group type: COMPARATOR
Intervention: Control (no change)
Number of subjects: 270
Study 18652321 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with reinforcing and reducing manipulation
Number of subjects: 0
Study 18652321 — intervention group
Group type: COMPARATOR
Intervention: Routine western medicine without acupuncture (Control)
Number of subjects: 0
Study 16863518 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic Glucantime (20 mg pentavalent antimony/kg/day) plus pentoxifylline (400 mg three times daily) for 20 days
Number of subjects: 64
Study 16863518 — intervention group
Group type: COMPARATOR
Intervention: Glucantime (20 mg pentavalent antimony/kg/day) plus placebo (three tablets daily) for 20 days
Number of subjects: 64
Study 15114430 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate aqueous nasal spray (MFANS) 50 microg/spray, 8 sprays per nostril every 8 h for 4 days
Number of subjects: 12
Study 15114430 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 50 microg/spray, 8 sprays per nostril every 8 h for 4 days
Number of subjects: 12
Study 15114430 — intervention group
Group type: COMPARATOR
Intervention: Placebo aqueous nasal spray (placebo ANS)
Number of subjects: 12
Study 11006179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ring (1g natural progesterone, continuous release for 90 days)
Number of subjects: 658
Study 11006179 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (i.m.) progesterone (50 mg/day for IVF; 100 mg/day for oocyte donation)
Number of subjects: 658
Study 11006179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ring
Number of subjects: 658
Study 11006179 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (i.m.) progesterone
Number of subjects: 658
Study 9438604 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (40 Gy with 5-fluorouracil as a sensitising agent)
Number of subjects: 348
Study 9438604 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months chemotherapy (5-fluorouracil and folinic acid)
Number of subjects: 348
Study 9438604 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy and chemotherapy
Number of subjects: 348
Study 9438604 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 348
Study 3537828 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavinton
Number of subjects: 57
Study 3537828 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 57
Study 29751849 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous compression stimulation (5-minute massage therapy)
Number of subjects: 32
Study 29751849 — intervention group
Group type: COMPARATOR
Intervention: Sham massage therapy (touch without compression)
Number of subjects: 32
Study 26806174 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compression-decompression CPR with CardioPump
Number of subjects: 181
Study 26806174 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 181
Study 25896113 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG immunisation
Number of subjects: 4184
Study 25896113 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 4184
Study 23098698 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nutmeg extracts (NEMM; mace oil [2%], nutmeg oil [14%], methyl salicylate [6%], menthol [6%], and coconut oil)
Number of subjects: 74
Study 23098698 — intervention group
Group type: COMPARATOR
Intervention: Placebo (MM; methyl salicylate [6%], menthol [6%], coconut oil, and alcohol)
Number of subjects: 74
Study 21072735 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise training (DET)
Number of subjects: 33
Study 21072735 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet (D)
Number of subjects: 33
Study 18708482 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention using the Drink-less package by a trained registered nurse
Number of subjects: 133
Study 18708482 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 133
Study 17003712 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory function improvement (self-assessed as 'better')
Number of subjects: 83
Study 17003712 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory function unchanged (self-assessed as 'unchanged')
Number of subjects: 83
Study 17003712 — intervention group
Group type: COMPARATOR
Intervention: Olfactory function deterioration (self-assessed as 'worse')
Number of subjects: 83
Study 17003712 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in TDI score
Number of subjects: 83
Study 14551526 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 100
Study 14551526 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 100
Study 14551526 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (including statins, ACE inhibitors, thienopyridines, aspirin, beta-blockers)
Number of subjects: 100
Study 14551526 — intervention group
Group type: COMPARATOR
Intervention: Revascularization (CABG or PCI)
Number of subjects: 100
Study 10975752 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (10 mg/kg/day) for 12 months after interferon therapy
Number of subjects: 203
Study 10975752 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 months after interferon therapy
Number of subjects: 203
Study 9273082 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual screening by serum PSA assay
Number of subjects: 0
Study 9273082 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic examinations (biopsy) and curative treatments (surgery or radiotherapy)
Number of subjects: 0
Study 9273082 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening recommendations
Number of subjects: 0
Study 8287314 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate disodium 75 mg
Number of subjects: 21
Study 8287314 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate disodium 150 mg
Number of subjects: 21
Study 8287314 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate disodium 300 mg
Number of subjects: 21
Study 8287314 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated peroral doses of pamidronate disodium (75 and 150 mg) for 10 consecutive days
Number of subjects: 21
Study 8287314 — intervention group
Group type: COMPARATOR
Intervention: i.v. infusion of pamidronate disodium 15 mg
Number of subjects: 21
Study 2953116 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexoprenalin 0.3 microgram/min
Number of subjects: 0
Study 2953116 — intervention group
Group type: COMPARATOR
Intervention: Celiprolol (3 X 100 micrograms oral)
Number of subjects: 0
Study 2953116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29433963 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab and pertuzumab plus metronomic oral cyclophosphamide
Number of subjects: 80
Study 29433963 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab and pertuzumab
Number of subjects: 80
Study 25762809 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video game play (Kinect Adventures on Xbox 360)
Number of subjects: 26
Study 25762809 — intervention group
Group type: COMPARATOR
Intervention: Resting control
Number of subjects: 26
Study 25762809 — intervention group
Group type: COMPARATOR
Intervention: Seated video game play (Xbox 360)
Number of subjects: 26
Study 24113579 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive video
Number of subjects: 0
Study 24113579 — intervention group
Group type: COMPARATOR
Intervention: Control video
Number of subjects: 0
Study 19763690 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbrella technique of mesh insertion
Number of subjects: 30
Study 19763690 — intervention group
Group type: COMPARATOR
Intervention: Roll-up technique of mesh insertion
Number of subjects: 30
Study 18398153 — intervention group
Group type: EXPERIMENTAL
Intervention: Bexarotene 400 mg/m(2)/d combined with carboplatin and paclitaxel
Number of subjects: 612
Study 18398153 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel alone
Number of subjects: 612
Study 16840727 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg once-daily lenalidomide
Number of subjects: 70
Study 16840727 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg twice-daily lenalidomide
Number of subjects: 70
Study 16840727 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (added in 68 patients)
Number of subjects: 70
Study 12741933 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg dexamethasone in 1 mL saline through one subcutaneous site (test site)
Number of subjects: 38
Study 12741933 — intervention group
Group type: COMPARATOR
Intervention: Control site (1 mL saline without dexamethasone)
Number of subjects: 38
Study 12840636 — intervention group
Group type: EXPERIMENTAL
Intervention: F(I)O(2) 0.26 (P(I)O(2) approximately 159 Torr)
Number of subjects: 19
Study 12840636 — intervention group
Group type: EXPERIMENTAL
Intervention: F(I)O(2) 0.60 (P(I)O(2) approximately 366 Torr)
Number of subjects: 19
Study 12840636 — intervention group
Group type: COMPARATOR
Intervention: Control trial (F(I)O(2) 0.21, P(I)O(2) approximately 128 Torr)
Number of subjects: 19
Study 10599357 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/day)
Number of subjects: 41
Study 10599357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 7573744 — intervention group
Group type: EXPERIMENTAL
Intervention: CUSUM analysis of postoperative SCCAg levels
Number of subjects: 75
Study 1672967 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice daily
Number of subjects: 100
Study 1672967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 6130595 — intervention group
Group type: EXPERIMENTAL
Intervention: oxprenolol (n = 10)
Number of subjects: 19
Study 6130595 — intervention group
Group type: COMPARATOR
Intervention: atenolol (n = 9)
Number of subjects: 19
Study 2932330 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraspinal EMG biofeedback
Number of subjects: 66
Study 2932330 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 66
Study 2932330 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 66
Study 31886682 — intervention group
Group type: EXPERIMENTAL
Intervention: Early substance involvement (heavy drinking, marijuana use, daily smoking, and other illicit drug use)
Number of subjects: 0
Study 31886682 — intervention group
Group type: EXPERIMENTAL
Intervention: Early smoking (cigarettes)
Number of subjects: 0
Study 31886682 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmarijuana illicit drugs
Number of subjects: 0
Study 31886682 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance experimentation prevention efforts
Number of subjects: 0
Study 29334309 — intervention group
Group type: EXPERIMENTAL
Intervention: Resisted sprint training (RST)
Number of subjects: 18
Study 29334309 — intervention group
Group type: COMPARATOR
Intervention: Unresisted sprint training (UR)
Number of subjects: 18
Study 28388963 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive distal pancreatectomy (MIDP)
Number of subjects: 102
Study 28388963 — intervention group
Group type: COMPARATOR
Intervention: Open distal pancreatectomy (ODP)
Number of subjects: 102
Study 25920290 — intervention group
Group type: EXPERIMENTAL
Intervention: BF + PFMT (biofeedback + pelvic floor muscle training)
Number of subjects: 61
Study 25920290 — intervention group
Group type: COMPARATOR
Intervention: PFMT (pelvic floor muscle training)
Number of subjects: 61
Study 23819423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 37.5 mg, Tinidazole 500 mg, Azithromycin 250 mg
Number of subjects: 50
Study 23819423 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole 37.5 mg, Tinidazole 500 mg, Clindamycin 312.5 mg
Number of subjects: 50
Study 20171350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 69
Study 20171350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 69
Study 20171350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 18655709 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive phone- and mail-based intervention
Number of subjects: 0
Study 18655709 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 18655709 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven day accelerometry data
Number of subjects: 0
Study 16997112 — intervention group
Group type: COMPARATOR
Intervention: Mandibular block using 2.1 mL of 2% lidocaine with 1:100 000 epinephrine for the inferior alveolar nerve, lingual nerve, and/or buccal nerve.
Number of subjects: 123
Study 16997112 — intervention group
Group type: COMPARATOR
Intervention: Control group (contralateral tooth)
Number of subjects: 123
Study 12544380 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium augmentation of nortriptyline
Number of subjects: 92
Study 12544380 — intervention group
Group type: COMPARATOR
Intervention: Placebo augmentation of nortriptyline
Number of subjects: 92
Study 10967487 — intervention group
Group type: EXPERIMENTAL
Intervention: Lippia multiflora essential oil (20% v/v) applied for 5 consecutive days
Number of subjects: 0
Study 10967487 — intervention group
Group type: COMPARATOR
Intervention: Benzyl benzoate preparation (same concentration as Lippia oil)
Number of subjects: 0
Study 10967487 — intervention group
Group type: EXPERIMENTAL
Intervention: Lippia multiflora essential oil
Number of subjects: 0
Study 10967487 — intervention group
Group type: EXPERIMENTAL
Intervention: Lippia multiflora essential oil in an enclosed system
Number of subjects: 0
Study 9100588 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose L (0.2 mg/kg)
Number of subjects: 22
Study 9100588 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose L (0.75 mg/kg)
Number of subjects: 22
Study 9100588 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose L (0.2 mg/kg) in fasted nonobese
Number of subjects: 22
Study 9100588 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose L (0.2 mg/kg) in fed nonobese
Number of subjects: 22
Study 9100588 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose L (0.2 mg/kg) in fasted obese
Number of subjects: 22
Study 9100588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8308943 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine abstinence treatment
Number of subjects: 19
Study 3541882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 102
Study 3541882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 29207899 — intervention group
Group type: EXPERIMENTAL
Intervention: Mat Pilates (MP) with TheraBand®
Number of subjects: 26
Study 29207899 — intervention group
Group type: COMPARATOR
Intervention: Calisthenics exercises (Control)
Number of subjects: 26
Study 27591236 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage
Number of subjects: 59
Study 27591236 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 59
Study 25173541 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5mg twice daily
Number of subjects: 1993
Study 25173541 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1993
Study 22683675 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 64
Study 22683675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 22683675 — intervention group
Group type: EXPERIMENTAL
Intervention: TIV in both years
Number of subjects: 64
Study 22683675 — intervention group
Group type: EXPERIMENTAL
Intervention: TIV in the first year
Number of subjects: 64
Study 19473807 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous tantalum acetabular component
Number of subjects: 17